A Phase 3 interventional study of Cannabidiol (CBD) and Placebo in Clinical High Risk for Psychosis (CHR), Clinical High Risk for Psychosis and Clinical High Risk for Developing Psychosis, sponsored by University of Oxford. Not yet recruiting at 19 sites in 10 countries. Open to participants aged 12 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-08.
Sponsored by University of Oxford · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing cannabidiol in Psychotic Disorders — 4 open to participants now, 5 under way, 4 of them phase 3. Cannabidiol · Psychotic Disorders.
Among the 11 studies testing cannabidiol in Psychotic Disorders, this one has the largest planned enrollment, is one of 2 that started in 2026, is one of 4 in phase 3, and was the 11th registered.
1,593 studies on the registry are indexed under Psychotic Disorders; 283 are open to participants now.
Browse Psychotic Disorders studies →4 of the 11 studies testing cannabidiol in Psychotic Disorders are open now, in 12 countries. Recruiting first, the newest first:
University of Oxford · Sites in Austria, Germany, Greece and 6 more countries
Ages 16–40
University of California, San Diego · Sites in United States
Ages 16–30
University of Oxford · Sites in Germany, Greece, Israel and 5 more countries
Ages 16–50
By country, each count listing its studies:
Cannabidiol: first FDA approval 2018 (EPIDIOLEX), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 204 Psychotic Disorders studies recruiting now, 53 (26%) set no upper age limit and 142 (70%) stop at 75 or younger; 50 take children under 18; 41 take healthy volunteers.
This study: 12 Years to 35 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 2 started in 2026.
This study's planned enrollment of 586 is above the median of 65 across 1,326 interventional studies indexed under Psychotic Disorders.
Median enrollment 64 across the 11 interventional studies. Of the 5 that completed or were terminated, 4 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 11 has an industry lead sponsor. The 6 most frequent:
University of Oxford is the lead sponsor of 813 studies on the registry; 119 are open to participants now.
University of Oxford has 4 studies filed under Psychotic Disorders — fewer than ten, so there is no comparison to draw.
1 of the studies testing cannabidiol in Psychotic Disorders that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04411225Phase 3University of California, San DiegoEffects of Cannabidiol (CBD) Versus Placebo as an Adjunct to Treatment in Early Psychosis | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies testing cannabidiol in Psychotic Disorders, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this trial is:
The trial is a randomised, double-blind, placebo-controlled, multi-centre, international clinical trial. Individuals meeting clinical high risk for psychosis criteria will be recruited for the trial intervention component of the trial. Participants are randomised to treatment with oral CBD 300mg (oral solution 100 mg/mL) twice daily, or a matching placebo, for 104 weeks. By using a battery of clinical outcome assessments, the trial will be able to assess several biomarkers to predict clinical outcomes and response to treatment with CBD. Participants will be invited to provide blood samples, stool samples, cerebrospinal fluid samples (if aged 18 years or over) and complete neuroimaging assessments. Individuals who are not found to have mental illness as defined by DSM-5 criteria will be recruited to a healthy control group, to validate the biomarker component of the trial.
Additionally, a control group of healthy volunteers will be recruited who will not take the trial intervention to aid calibration between datasets from sites acquiring MRI data and to inform and validate any possible multivariate signature associated with the CHR-P state, course or outcome by understanding how these measures are different in controls. Healthy controls will also be used for secondary case-control comparisons. Healthy controls will undergo clinical and biomarker assessments only.
CHR-P patients:
Inclusion Criteria
The age range for eligibility has been applied as this corresponds to the usual age range for a clinical high-risk state; individual cases outside of this age range may have a different aetiology and/or prognosis which could impact on the trial outcomes.
There is inadequate information on the effects of cannabidiol on the foetus in humans. Participants of childbearing potential* should use a highly effective method of contraception** for the duration of the trial and for 3 months after the last time the trial intervention was used. There is no special requirement for male participants to use highly effective contraception as there are no known safety concerns in males, such as sperm toxicity, as per the investigator's brochure. This trial will also not be collecting male participant partner pregnancy data.
*A person is considered of childbearing potential, i.e. fertile, following menarche and until becoming unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause.
** Methods that can achieve a failure rate of less than 1% per year when used consistently and correctly are considered as highly effective birth control methods. Such methods include: 1) combined (oestrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral; intravaginal; transdermal); 2) progestogen-only hormonal contraception associated with inhibition of ovulation (oral; injectable; implantable); 3) intrauterine device (IUD); 4) intrauterine hormone-releasing system (IUS); 5) bilateral tubal occlusion; 6) vasectomised partner; 7) sexual abstinence (abstinence should only be used as a contraceptive method if it is in line with the participants' usual and preferred lifestyle).
Periodic abstinence (calendar, symptothermal, post-ovulation methods) is not an acceptable method of contraception. The participant agrees to use an acceptable method of contraception for the duration of the trial and for 3 months after any trial drug administration, unless surgically sterile or postmenopausal (no menses for 12 months without an alternative medical cause).
Exclusion Criteria
Traumatic brain injury that is rated as 7 or above on the Traumatic Brain Injury screening instrument.
Minor neurological disorders such as migraine, other minor headache disorders, sleep disorders or nerve palsies that are unlikely to affect trial or biomarker outcomes can be permitted.
If at screening, a potential participant is prescribed an antipsychotic at a dose ≥ minimum effective dose for treating FEP, they may be re-screened for trial participation at a later date if the dose is subsequently reduced below threshold for at least 2 weeks. Any decision to do so will be the responsibility of the treating clinician and must ensure that it is both safe and ethical to do so. Specialist advice will be made available and be provided by clinicians experienced in managing CHR-P at University of Oxford and King's College London.
Healthy controls:
Inclusion Criteria
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will take the intervention for 106 weeks (104 weeks plus a 2-week taper). Doses depend on age and weight: Adults (16 years and older) over 50kg: daily dose 600mg (6ml); 300mg (3ml) twice a day (b.i.d); Adults (16 years and older) less than 50kg: daily dose 10mg/kg; 5mg/kg twice a day (b.i.d); Children (\<16 years old): daily dose 5mg/kg twice a day (b.i.d), following on from a two-week rapid titration schedule. n=188
Drug: Cannabidiol (CBD)
Participants will take the intervention for 106 weeks (104 weeks plus a 2-week taper). Doses depend on age and weight: Adults (16 years and older) over 50kg: daily dose 600mg (6ml); 300mg (3ml) twice a day (b.i.d). Adults (16 years and older) less than 50kg: daily dose 10mg/kg; 5mg/kg twice a day (b.i.d). Children (\<16 years old): daily dose 5mg/kg twice a day (b.i.d), following on from a two-week rapid titration schedule. n=188
Drug: Placebo
A healthy control in the context of this trial is someone who does not meet CHR-P criteria or have a diagnosis of a mental health condition. They will not take the trial intervention and attend one trial visit for clinical assessments and biomarker sampling only. n=150
CBD 100 mg/mL Oral Solution
Placebo for Cannabidiol oral solution 100mg/mL oral solution
ChaChange from baseline in attenuated positive psychotic symptoms (CAARMS P1-P4 positive symptom subscale score)
Change from baseline to Week 104 in the positive symptom subscale score (P1-P4) of the Comprehensive Assessment of At-Risk Mental States (CAARMS). Higher scores indicate greater symptom severity.
Time frame: Baseline to Week 104
Change in attenuated psychotic symptoms (Comprehensive Assessment of At-Risk Mental States, CAARMS total score)
Change from baseline to Week 4 in CAARMS (Comprehensive Assessment of At-Risk Mental States) total score
Time frame: Baseline to Week 4
Change in attenuated psychotic symptom subscale scores (Comprehensive Assessment of At-Risk Mental States, CAARMS P1-P4)
Change from baseline to Week 4 in Comprehensive Assessment of At-Risk Mental States (CAARMS) P1-P4 subscale scores.
Time frame: Baseline to Week 4
Change in distress associated with attenuated psychotic symptoms
Change from in Comprehensive Assessment of At-Risk Mental States (CAARMS) distress scores.
Time frame: Baseline to Week 4
Change in anxiety symptoms (Hamilton Anxiety Rating Scale, HAM-A)
Change from baseline to Week 4 in Hamilton Anxiety Rating Scale (HAM-A) total score.
Time frame: Baseline to Week 4
Change in anxiety symptoms (Overall Anxiety Severity and Impairment Scale, OASIS)
Change from baseline to Week 4 in Overall Anxiety Severity and Impairment Scale (OASIS) score
Time frame: Baseline to Week 4
Remission from Clinical High-Risk for Psychosis (CHR-P) state
Proportion of participants meeting Comprehensive Assessment of At-Risk Mental States (CAARMS) remission criteria at Week 4.
Time frame: Baseline to Week 4
Change in quality of life (EQ-5D-3L index score)
Change from baseline to Week 4 in EQ-5D-3L index score.
Time frame: Baseline to Week 4
Change in quality of life (WHOQOL-BREF total score)
Change from baseline to Week 4 in WHOQOL-BREF total score.
Time frame: Baseline to Week 4
All-cause treatment discontinuation
Proportion of participants who discontinue study treatment for any reason by Week 4.
Time frame: Baseline to Week 4
Incidence of adverse events
Number of participants with one or more adverse events by Week 4.
Time frame: Baseline to Week 4
Severity of adverse events (Glasgow Antipsychotic Side-effect Scale, GASS total score)
Change from baseline to Week 4 in Glasgow Antipsychotic Side-effect Scale (GASS) total score.
Time frame: Baseline to Week 4
Change in clinician-rated global severity (Clinical Global Impressions (CGI) scale- - Severity, CGI-S)
Change from baseline to Week 4 in Clinical Global Impressions scale- - Severity (CGI-S) score.
Time frame: Baseline to Week 4
Change in clinician-rated global severity (Clinical Global Impressions (CGI) scale- - Improvement, CGI-I)
Change from baseline to Week 4 in Clinical Global Impressions scale- - Improvement (CGI-I) score.
Time frame: Baseline to Week 4
Change in patient-rated global severity (Patient Global Imression of Improvement, PGI-I)
Change from baseline to Week 4 in Patient Global Imression of Improvement (PGI-I) score.
Time frame: Baseline to Week 4
Change in patient-rated global severity (Patient Global Impression of Severity, PGI-S)
Change from baseline to Week 4 in Patient Global Imression of Severity (PGI-S) score.
Time frame: Baseline to Week 4
Change in attenuated psychotic symptoms (Comprehensive Assessment of At-Risk Mental States, CAARMS total score)
Time frame: Baseline to Week 104
Change in attenuated psychotic symptom subscale scores (Comprehensive Assessment of At-Risk Mental States, CAARMS P1-P4)
Time frame: Baseline to Week 104
Change in anxiety symptoms (Hamilton Anxiety Rating Scale , HAM-A)
Time frame: Baseline to Week 104
Change in anxiety symptoms (Overall Anxiety Severity and Impairment Scale, OASIS)
Time frame: Baseline to Week 104
Change in global functioning (Social and Occupational Functioning Assessment Scal, SOFAS)
Time frame: Baseline to Week 104
Change in cognitive functioning (PsyCog battery composite score)
Time frame: Baseline to Week 104
Transition to psychosis
Proportion of participants meeting Comprehensive Assessment of At-Risk Mental States (CAARMS) criteria for transition to psychosis. Biomarker data (neuroimaging, peripheral blood, microbiome, metabolomics, proteomics, CSF and environmental measures) will be used in exploratory modelling analyses to develop prognostic and predictive algorithms for transition to psychosis and treatment response.
Time frame: Baseline to Week 104
Remission from Clinical High-Risk for Psychosis (CHR-P) state
Time frame: Baseline to Week 104
Change in quality of life (EQ-5D-3L)
Time frame: Baseline to Week 104
Change in quality of life (WHOQOL-BREF)
Time frame: Baseline to Week 104
All-cause treatment discontinuation
Time frame: Baseline to Week 104
Incidence of adverse events
Time frame: Baseline to Week 104
Severity of adverse events (Glasgow Antipsychotic Side-effect Scale, GASS)
Time frame: Baseline to Week 104
Change in clinician-rated global impression (CGI)
Time frame: Baseline to Week 104
Change in patient-rated global impression (PGI)
Time frame: Baseline to Week 104
Diagnosis of mental disorders
Proportion of participants diagnosed with a mental disorder based on clinical record review. Biomarker data (neuroimaging, peripheral blood, microbiome, metabolomics, proteomics, CSF and environmental measures) will be used in exploratory modelling analyses to develop prognostic and predictive algorithms for transition to psychosis and treatment response.
Time frame: Baseline, Week 104, and 4 years post-baseline
Prescription of psychotropic medication
Proportion of participants prescribed psychotropic medication. Biomarker data (neuroimaging, peripheral blood, microbiome, metabolomics, proteomics, CSF and environmental measures) will be used in exploratory modelling analyses to develop prognostic and predictive algorithms for transition to psychosis and treatment response.
Time frame: Baseline, Week 104, and 4 years post-baseline
Psychiatric hospital or emergency department admission
Proportion of participants admitted to psychiatric hospital or emergency services. Biomarker data (neuroimaging, peripheral blood, microbiome, metabolomics, proteomics, CSF and environmental measures) will be used in exploratory modelling analyses to develop prognostic and predictive algorithms for transition to psychosis and treatment response.
Time frame: Baseline, Week 104, and 4 years post-baseline
Number of healthcare appointments
Total number of healthcare appointments recorded. Biomarker data (neuroimaging, peripheral blood, microbiome, metabolomics, proteomics, CSF and environmental measures) will be used in exploratory modelling analyses to develop prognostic and predictive algorithms for transition to psychosis and treatment response.
Time frame: Baseline to 4 years post-baseline
Mortality (including suicide)
All-cause mortality, including suicide. Biomarker data (neuroimaging, peripheral blood, microbiome, metabolomics, proteomics, CSF and environmental measures) will be used in exploratory modelling analyses to develop prognostic and predictive algorithms for transition to psychosis and treatment response.
Time frame: Baseline to 4 years post-baseline
Change in environmental risk score (Psychosis Polyrisk Score, PPS)
Time frame: Baseline to Week 104
Change in psychopathology (Semi-structured Interview for Bipolar At Risk States, SIBARS score)
Time frame: Baseline to Week 104
Change in psychopathology (Young Mania Rating Scale, YMRS score)
Time frame: Baseline to Week 104
Change in borderline personality features (McLean Screening Instrument for borderline personality disorder, MSI-BPD score)
Time frame: Baseline to Week 104
Change in daily functioning (Functional Remission of General Schizophrenia, FROGS score)
Time frame: Baseline to Week 104
Change in physical activity (Simple Physical Activity Questionnaire, SIMPAQ score)
Time frame: Baseline to Week 104
Change in resilience (Resilience Scale for Adults, RSA score)
Time frame: Baseline to Week 104
Change in substance use (Alcohol, Smoking and Substance Involvement Screening Tool, ASSIST score)
Time frame: Baseline to Week 104
Plan to share: Yes — Please contact the sponsor, who will provide instructions for submitting a data request. All data can be requested, regardless of the location of the requesting party.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Data and supporting documents will become available once the primary papers are available in the scientific domain.
Access criteria: These will be provided by the sponsor to the requesting party.
No publications or documents are linked to this record.
Start is estimated for Dec 2026; primary completion for Dec 2029, 36 months later.
Of 26 phase 3 interventional studies under Psychotic Disorders, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 72. This study's planned 36 months is close to that.
Start moved once since we started tracking on Sep 25, 2026: May 2026 → Dec 2026, on Oct 8, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cannabidiol